Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Nov 5;33(11):5338-5354.
doi: 10.1016/j.ymthe.2025.08.013. Epub 2025 Aug 9.

Direct in vivo reprogramming to relieve tissue ischemia via induced vasculogenesis

Affiliations
Review

Direct in vivo reprogramming to relieve tissue ischemia via induced vasculogenesis

Mervin C Yoder et al. Mol Ther. .

Abstract

There is an ongoing need for innovative cell and regenerative medicine therapies to promote vascular repair and regeneration to meet the growing global health concern of ischemic cardiovascular diseases. Direct reprogramming of somatic cells into an induced pluripotent state caused scientists to reconsider prior theories of cell differentiation and develop approaches to directly reprogram cells in vivo into other states or fates to adaptively replace cells lost to aging or disease. While direct in vivo reprogramming of fibroblast to cardiomyocytes, neurons, or pancreatic beta islet cell states has been studied since 2008, direct in vivo reprogramming of fibroblasts into induced vasculogenic cells was not reported until 2017. This review provides a brief overview of the field of in vitro direct reprogramming of fibroblasts into induced endothelial cells over the past decade and identifies key similarities and differences in approaches. The primary focus of this review is to discuss in detail 4 published reports of direct in vivo reprogramming of fibroblasts into vasculogenic cell states and identify a series of questions for future studies that will clarify the reprogrammed cells and potential for using these approaches for translation into larger preclinical models or human subjects.

Keywords: in vivo reprogramming; regenerative medicine; tissue nanotransfection; vasculogenic fibroblast; wound.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Figures

Figure 1.
Figure 1.
Overall outline of direct in vitro (A.) or in vivo (B.) reprogramming of fibroblasts into fibroblast-derived vasculogenic cells (also called induced endothelial cells). Abbreviations not spelled out in Figure: FACS, fluorescent activated cell (sorting) or flow cytometric cell profiling; IHC, immunohistochemistry; qRT-PCR, quantitative reverse transcriptase-PCR; scRNAseq, single cell RNA sequencing.
Figure 2.
Figure 2.
Emergence of skin vasculogenic fibroblasts upon injury and role in vascular regeneration. Vasculogenic fibroblast (VF) cells are rare in uninjured tissue. Upon injury (acute skin wounding that causes ischemia and hypoxia to wound edge tissue as example), VF emerge from tissue fibroblasts (blue star shaped cells) and migrate into nascent blood vessels to integrate into the endothelial intima as well as, localizing in a peri-endothelial location to secrete proangiogenic molecules to enhance revascularization, improve perfusion, and promote healing in nondiabetic and diabetic subjects. Thus, fibroblasts physiologically display a state change to display vasculogenic functions (VF) that directly participate in enhancing vessel repair and regeneration.

References

    1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, et al. (2020). Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. J Am Coll Cardiol 76, 2982–3021. 10.1016/j.jacc.2020.11.010. - DOI - PMC - PubMed
    1. Bottardi A, Prado GFA, Lunardi M, Fezzi S, Pesarini G, Tavella D, Scarsini R, and Ribichini F (2024). Clinical Updates in Coronary Artery Disease: A Comprehensive Review. J Clin Med 13. 10.3390/jcm13164600. - DOI - PMC - PubMed
    1. Choudhury P, Kandula N, Kosuru R, and Adena SKR (2024). Nanomedicine: A great boon for cardiac regenerative medicine. Eur J Pharmacol 982, 176969. 10.1016/j.ejphar.2024.176969. - DOI - PubMed
    1. Pang B, Dong G, Pang T, Sun X, Liu X, Nie Y, and Chang X (2024). Advances in pathogenesis and treatment of vascular endothelial injury-related diseases mediated by mitochondrial abnormality. Front Pharmacol 15, 1422686. 10.3389/fphar.2024.1422686. - DOI - PMC - PubMed
    1. Annex BH (2013). Therapeutic angiogenesis for critical limb ischaemia. Nat Rev Cardiol 10, 387–396. 10.1038/nrcardio.2013.70. - DOI - PubMed

LinkOut - more resources